Additional Dose of Intravenous Dexamethasone Can Replace Patient-Controlled Analgesia in Pain Control after Total Knee Arthroplasty while Reducing Opioid Complications

Abstract

The purpose of this study was to evaluate whether intravenous (IV) dexamethasone, within the current multimodal pain management protocol, (1) could maintain postoperative pain at a comparable level without IV patient-controlled analgesia (PCA), (2) could reduce opioids-related side effects, and (3) whether an additional dose of dexamethasone on postoperative day (POD) 2 would offer further pain-relieving effect without increasing the risk of complications. A total of 178 patients (182 knees) who underwent total knee arthroplasty for osteoarthritis were included in the study. The patients were divided into Dexa 2 & PCA and Dexa 3 & NoPCA groups. From operative day to POD 5, pain visual analogue score (VAS), rescue opioids consumption, episodes of postoperative nausea and vomiting (PONV), antiemetics usage, and side effects of opioids such as postoperative urinary retention (POUR) and constipation were checked. For safety, wound complication and infection were checked. There was no difference in pain VAS between the two groups during all six perioperative days. Rescue opioids consumption was lower in Dexa 2 & PCA group. Total dosage of used opioids for six perioperative days was lower in Dexa 3 & NoPCA group. Dexa 3 & NoPCA group had less PONV and POUR. There was a marked increase in pain VAS and the use of rescue opioids from POD 1 to POD 2 in the Dexa 2 & PCA. There were no wound problems or infections in either group. Under the current multimodal pain management protocol, comparable level of postoperative pain could be achieved by dexamethasone without the need of IV PCA. By not using IV PCA, overall opioid usage was reduced, which could lead to a lower frequency of PONV and POUR. While there is still room for further research on the duration and frequency of administering dexamethasone, additional administration on POD 2 is believed to provide additional pain management benefits compared with administering only until POD 1.

Keywords

total knee arthroplasty - perioperative management - postoperative pain - postoperative nausea and vomiting - dexamethasone

Publikationsverlauf

Eingereicht: 24. Januar 2024

Angenommen: 01. Januar 2025

Accepted Manuscript online:
03. Januar 2025

Artikel online veröffentlicht:
19. März 2025

• References

• 1 Akbari GA, Erdi AM, Asri FN. Comparison of fentanyl plus different doses of dexamethasone with fentanyl alone on postoperative pain, nausea, and vomiting after lower extremity orthopedic surgery. Eur J Transl Myol 2022; 32 (02) 10397
• 2 Goto S, Kasuya Y, Okuyama K, Ikari K, Ozaki M. Impeding factors of early rehabilitation postoperatively after rheumatoid toe arthroplasty: a single-center retrospective cohort study. JA Clin Rep 2020; 6 (01) 50
• 3 Choi YS, Kim TW, Chang MJ, Kang SB, Chang CB. Enhanced recovery after surgery for major orthopedic surgery: a narrative review. Knee Surg Relat Res 2022; 34 (01) 8
• 4 Wainwright TW, Gill M, McDonald DA. et al. Consensus statement for perioperative care in total hip replacement and total knee replacement surgery: Enhanced Recovery After Surgery (ERAS) Society recommendations. Acta Orthop 2020; 91 (01) 3-19
• 5 Dolin SJ, Cashman JN. Tolerability of acute postoperative pain management: nausea, vomiting, sedation, pruritus, and urinary retention. Evidence from published data. Br J Anaesth 2005; 95 (05) 584-591
• 6 Colvin LA, Bull F, Hales TG. Perioperative opioid analgesia-when is enough too much? A review of opioid-induced tolerance and hyperalgesia. Lancet 2019; 393 (10180): 1558-1568
• 7 Hah JM, Bateman BT, Ratliff J, Curtin C, Sun E. Chronic opioid use after surgery: implications for perioperative management in the face of the opioid epidemic. Anesth Analg 2017; 125 (05) 1733-1740
• 8 Lamplot JD, Wagner ER, Manning DW. Multimodal pain management in total knee arthroplasty: a prospective randomized controlled trial. J Arthroplasty 2014; 29 (02) 329-334
• 9 Vendittoli P-A, Makinen P, Drolet P. et al. A multimodal analgesia protocol for total knee arthroplasty. A randomized, controlled study. J Bone Joint Surg Am 2006; 88 (02) 282-289
• 10 Weibel S, Rücker G, Eberhart LH. et al. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis. Cochrane Database Syst Rev 2020; 10 (10) CD012859
• 11 Samuel S, Nguyen T, Choi HA. Pharmacologic characteristics of corticosteroids. J Neurocrit Care 2017; 10 (02) 53-59
• 12 Parente L. Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids. BMC Pharmacol Toxicol 2017; 18 (01) 1
• 13 Fan Z, Ma J, Kuang M. et al. The efficacy of dexamethasone reducing postoperative pain and emesis after total knee arthroplasty: a systematic review and meta-analysis. Int J Surg 2018; 52: 149-155
• 14 Zhuo Y, Yu R, Wu C, Huang Y, Ye J, Zhang Y. The role of perioperative intravenous low-dose dexamethasone in rapid recovery after total knee arthroplasty: a meta-analysis. J Int Med Res 2021; 49 (03) 300060521998220
• 15 Ruberto RA, Farah O, Lopez C, Hickernell T. Perioperative intravenous glucocorticoids in total joint arthroplasty: a systematic review. J Am Acad Orthop Surg 2023; 31 (02) e94-e106
• 16 Liang S, Xing M, Jiang S, Zou W. Effect of intravenous dexamethasone on postoperative pain in patients undergoing total knee arthroplasty: a systematic review and meta-analysis. Pain Physician 2022; 25 (02) E169-E183
• 17 Lex JR, Edwards TC, Packer TW, Jones GG, Ravi B. Perioperative systemic dexamethasone reduces length of stay in total joint arthroplasty: a systematic review and meta-analysis of randomized controlled trials. J Arthroplasty 2021; 36 (03) 1168-1186
• 18 Wu L, Si H, Li M. et al. The optimal dosage, route and timing of glucocorticoids administration for improving knee function, pain and inflammation in primary total knee arthroplasty: a systematic review and network meta-analysis of 34 randomized trials. Int J Surg 2020; 82: 182-191
• 19 Hannon CP, Fillingham YA, Mason JB. et al. The efficacy and safety of corticosteroids in total joint arthroplasty: a direct meta-analysis. J Arthroplasty 2022; 37 (10) 1898-1905.e7
• 20 Wasko MK, Bobecka-Wesołowska K, Tomasiuk R, Kowalczewski J. Measurement of the inflammatory response in the early postoperative period after hip and knee arthroplasty. Clin Chem Lab Med 2015; 53 (11) 1785-1792
• 21 Lebleu J, Pauwels A, Poilvache H, Anract P, Belbachir A. Severe postoperative pain in total knee arthroplasty patients: risk factors, insights and implications for pain management via a digital health approach. J Clin Med 2023; 12 (24) 7695
• 22 Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain - United States, 2022. MMWR Recomm Rep 2022; 71 (03) 1-95
• 23 Ballstaedt LWB. Bladder Post Void Residual Volume. StatPearls; 2023
• 24 Khan MI, Khandadashpoor S, Rai Y, Vertolli G, Backstein D, Siddiqui N. Comparing analgesia on an as-needed basis to traditional intravenous patient-controlled analgesia within fast-track orthopedic procedures: a randomized controlled trial. Pain Manag Nurs 2022; 23 (06) 832-837
• 25 Wheeler M, Oderda GM, Ashburn MA, Lipman AG. Adverse events associated with postoperative opioid analgesia: a systematic review. J Pain 2002; 3 (03) 159-180
• 26 Barra MF, Kaplan NB, Balkissoon R, Drinkwater CJ, Ginnetti JG, Ricciardi BF. Same-day outpatient lower-extremity joint replacement: a critical analysis review. JBJS Rev 2022; 10 (06)
• 27 Denham M, Donovan K, Wetoska N. et al. Effects of dexamethasone on postoperative urinary retention after laparoscopic inguinal hernia repair. Surg Endosc 2019; 33 (09) 3008-3013
• 28 Broderick RC, Li JZ, Blitzer RR. et al. A steady stream of knowledge: decreased urinary retention after implementation of ERAS protocols in ambulatory minimally invasive inguinal hernia repair. Surg Endosc 2022; 36 (09) 6742-6750
• 29 Schimmer BP, Parker KL. Adrenocorticotropic Hormone; Adrenocortical Steroids and Their Synthetic Analogs; Inhibitors of the Synthesis and Actions of Adrenocortical Hormones. Goodman & Gilmans the Pharmacological Basis of Therapeutics. 11th ed.. New York: McGraw Hill; 2006: 1587-1612
• 30 Saini MK, Reddy NR, Reddy PJ, Thakur AS, Reddy CD. The application of low-dose dexamethasone in total knee arthroplasty: finding out the best route and dosage schedule. Arch Orthop Trauma Surg 2023; 143 (02) 1005-1012
• 31 Lei Y, Huang Z, Huang Q, Pei F, Huang W. Dose optimization of intravenous dexamethasone for total knee arthroplasty: when two is not better than one. Arch Orthop Trauma Surg 2022; 142 (04) 665-672
• 32 Kim JK, Ro DH, Lee HJ, Park JY, Han HS, Lee MC. Efficacy of systemic steroid use given one day after total knee arthroplasty for pain and nausea: a randomized controlled study. J Arthroplasty 2020; 35 (01) 69-75
• 33 Xu H, Zhang S, Xie J, Lei Y, Cao G, Pei F. Multiple doses of perioperative dexamethasone further improve clinical outcomes after total knee arthroplasty: a prospective, randomized, controlled study. J Arthroplasty 2018; 33 (11) 3448-3454
• 34 Lei Y, Huang Q, Xu B, Zhang S, Cao G, Pei F. Multiple low-dose dexamethasone further improves clinical outcomes following total hip arthroplasty. J Arthroplasty 2018; 33 (05) 1426-1431
• 35 Armaghani SJ, Lee DS, Bible JE. et al. Preoperative opioid use and its association with perioperative opioid demand and postoperative opioid independence in patients undergoing spine surgery. Spine 2014; 39 (25) E1524-E1530
• 36 Pivec R, Issa K, Naziri Q, Kapadia BH, Bonutti PM, Mont MA. Opioid use prior to total hip arthroplasty leads to worse clinical outcomes. Int Orthop 2014; 38 (06) 1159-1165